What's next after 50 years of psychiatric drug development: An FDA perspective

Journal of Clinical Psychiatry

Volumn 71, Issue 9, 2010, Pages 1196-1204

  Laughren, Thomas P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CODEINE; DESIPRAMINE; DESVENLAFAXINE; FLUOXETINE PLUS OLANZAPINE; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SERTRALINE; TRASTUZUMAB; ZIPRASIDONE; NEW DRUG; PSYCHOTROPIC AGENT;

ACUTE CORONARY SYNDROME; AGITATION; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BIPOLAR MANIA; BREAST CANCER; BULIMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG METABOLISM; DRUG PACKAGING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MENTAL DISEASE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; STEVENS JOHNSON SYNDROME; SUICIDE; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG REACTION; FORECASTING; LEGISLATION AND JURISPRUDENCE; POSTMARKETING SURVEILLANCE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

DRUG APPROVAL; DRUG DISCOVERY; DRUG TOXICITY; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77957844776     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06262gry     Document Type: Review

References (56)

1. About FDA. US Food and Drug Administration Web site. http://www.fda.gov/ AboutFDA/WhatWeDo/WhatFDARegulates/default.htm. Updated December 2, 2009. Accessed May 19, 2010.
2. Federal Food, Drug, and Cosmetic Act (FD&C Act). US Food and Drug Administration Web site. http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/default.htm. Updated March 5, 2010. Accessed May 19, 2010.
3. Sec 505. [21 USC §355] New Drugs. FD&C Act Chapter 5: Drugs and Devices. US Food and Drug Administration Web site. http://www.fda.gov/ RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/ FDCActChapterVDrugsandDevices/ucm108125.htm. Updated April 30, 2009; accessed May 19, 2010.
4. CFR - Code of Federal Regulations Title 21. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?fr=314.126&SearchTerm= adequate%20and%20well%2Dcontrolled%20investigations. Updated April 1, 2009. Accessed May 19, 2010.
5. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry. 2001;16(7):418-423. doi:10.1016/S0924-938(01)060-9 PubMed
6. Code of Federal Regulations Title 21. Part 312. Investigational New Drug Application. US Food and Drug Administration Web site. http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312. Updated April 1, 2009. Accessed May 19, 2010.
7. Code of Federal Regulations Title 21. Part 314. Applications for FDA approval to market a new drug. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart= 314. Updated April 1, 2009. Accessed May 19, 2010.
8. MedWatch the FDA Safety Information and Adverse Event Reporting Program. Antipsychotics, Conventional and Atypical. US Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm110212.htm. Updated June 19, 2009. Accessed May 19, 2010.
9. Laughren TP. A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):340-345. PubMed
10. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19. doi:10.1093/schbul/sbi020 PubMed
11. Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull. 2006;32(2):220-222. doi:10.1093/schbul/sbi039 PubMed
12. Laughren TP. Comorbid mood disorders and medical illness: a Food and Drug Administration perspective. Biol Psychiatry. 2003;54(3):195-199. doi:10.1016/S06-323(03)0529-8 PubMed
13. Guideline for Industry. Studies in Support of Special Populations: Geriatrics. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM129519.pdf. Accessed May 19, 2010.
14. Center for Drug Evaluation and Research. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072044.pdf. Accessed May 19, 2010.
15. US Food and Drug Administration. Food and Drug Administration Modernization Act of 1997 §111 of Title I; Federal Food, Drug, and Cosmetic Act §505A, 21USC §355a.
16. US Food and Drug Administration. Pediatric Drug Development. FDA Amendments Act of 2007. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/ucm049867.htm.
17. US Food and Drug Administration. CFR: Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr= 314.50.
18. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Dose-Response Information to Support Drug Registration. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073115.pdf.
19. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology. 2003;28(3):552-557. doi:10.1038/sj.np.13059 PubMed
20. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40. doi:10.1016/j.euroneuro.208.08.09 PubMed
21. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PubMed
22. Clinical Trials.gov. Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac). http://clinicaltrials.gov/ct2/show/ NCT00418171. Accessed May 19, 2010.
23. Peuskens J, Tanghøj P, Mittoux A, et al. The Sertindole Cohort Prospective (SCoP) study. http://www.ncbi.nlm.nih.gov/pubmed/18384186. Accessed May 19, 2010.
24. Siddiqui O, Hung HMJ, O'Neill R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19(2):227-246. doi:10.1080/1054340802609797 PubMed
25. US Food and Drug Administration. Critical Path Initiative. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default. htm. Accessed May 19, 2010.
26. US Food and Drug Administration. Critical Path Initiative. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf. Accessed May 19, 2010.
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed
28. Agency for Healthcare Research and Quality. Treatment of Depression: Newer Pharmacotherapies. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= hserta&part=A9274. Accessed May 19, 2010.
29. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.176/api.ajp.163.1.1905 PubMed
30. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26-36. doi:10.101/archgenpsychiatry.209.175 PubMed
31. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2008. doi:10.1093/schbul/sbn10 PubMed
32. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-590. doi:10.2165/0308-2054060-02 PubMed
33. Madadi P, Ross CJD, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85(1):31-35. doi:10.1038/clpt.208.157 PubMed
34. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1986;40(5):543-549. PubMed
35. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652-1654. doi:10.1056/NEJMp058197 PubMed
36. Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol. 2009;18(1):22-29. doi:10.1097/PDM.0b013e31818ebc69 PubMed
37. US National Library of Medicine, National Institutes of Health. Daily Med: Herceptin (trastuzumab) kit for intravenous use (Genentech). http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=herceptin&x= 14&y=10. Accessed May 19, 2010.
38. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257. PubMed (Pubitemid 46328503)
39. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814. doi:10.1086/503820 PubMed
40. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49(2):542-546. PubMed
41. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297-306. doi:10.1097/01.fpc.01950.46842.4a PubMed
42. US Food and Drug Administration. Newly Added Guidance Documents. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm121568.htm. Accessed May 19, 2010.
43. US Food and Drug Administration. Guidance for Industry: End-of-Phase 2A Meetings. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/uidances/ucm079690.pdf. Accessed May 19, 2010.
44. Insel TR, Wang PS. Rethinking mental illness. JAMA. 2010;303(19):1970- 1971. doi:10.101/jama.2010.5 PubMed
45. Guidance for Industry Providing Regulatory Submissions in Electronic Format: Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. US Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072349.pdf. Accessed May 19, 2010.
46. Clinical Data Interchange Standards Consortium. http://www.cdisc.org. Accessed May 19, 2010.
47. Health Level Seven International (HL7). http://www.hl7.org/about/index. cfm. Accessed May 19, 2010.
48. DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatry. 2008;20(1):21-31. doi:10.1080/1040123070184612 PubMed
49. US Food and Drug Administration. http://inside.fda.gov:9003/downloads/ ProgramsInitiatives/Drugs/SafetyFirst/ucm055469.pdf. Accessed July 8. 2010.
50. Department of Health and Human Services. Food and Drug Administration. Report to Congress. Changing the Future of Drug Safety: FDA Initiatives to Strengthen and Transform the Drug Safety System. http://www.fda.gov/downloads/ Safety/SafetyofSpecificProducts/UCM184046.pdf. Accessed May 19, 2010.
51. US Food and Drug Administration. FDA's Sentinel Initiative. http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm. Accessed May 19, 2010.
52. US Food and Drug Administration. Safe Use Initiative. http://www.fda.gov/Drugs/DrugSafety/ucm187806.htm. Update December 12, 2009. Accessed May 19, 2010.
53. Hammad TA, Laughren TP, Racoosin JA. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. doi:10.101/archpsyc.63.3.32 PubMed (Pubitemid 43345358)
54. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880. doi:10.136/bmj.b280 PubMed
55. US Food and Drug Administration. Information for Healthcare Professionals: Conventional Antipsychotics. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Updated November 5, 2009. Accessed May 19, 2010.
56. US Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153478.htm. Accessed May 19, 2010.